Issue link: https://www.e-digitaleditions.com/i/1543258
Inhalation February 2026 25 10 years of transformation Merxin, Ltd designs and supplies dry powder inhalers (DPIs) and soft mist inhalers (SMIs) that support the delivery of groundbreaking inhaled therapies. Our MRX003 capsule DPI is on the market; MRX004 SMI is the preferred choice for biologics and high- dose delivery, featuring tuneable emitted dose vol- ume; MRX006, our multidose dry powder inhaler is a favorite for performance and ease of use. We also sup- ply MRX002+ a transparent canister for LGWP HFA/ HFO pMDI formulations. Our inhalers are commer- cially successful and designed for therapies with low global warming potential. Be in touch to enhance the delivery of your therapy. Let's build the future together. #WeMakeInhalers. #WeWillLaunchYou. Merxin Ltd UK: +44 1553 403070 info@merxin.com www.merxin.com PFAS-free MDI canister coating Big changes are coming, especially related to future per- and polyfluoroalkyl substances (PFAS) bans. Biomerics can help you stay out in front of them with our new, patent pending, 100% PFAS-free metered dose inhaler (MDI) canister coating. So far, pharma- ceutical test results show equivalency to current PFAS coatings. Please reach out to us and let us know how we can support your MDI projects. Biomerics US: +1 540 246-1930 rchurchill@biomerics.com www.biomerics.com pMDI technology and product development i2c Pharmaceutical Services is an experienced service provider for the development of pharmaceutical for- mulations. Respitab is a propellant dispersible tablet that eliminates the need for complex mixing processes used in standard pressurized metered dose inhaler (pMDI) manufacturing. is patented, innovative platform enables transition to low global warming potential (GWP) pMDIs for a range of active pharma- ceutical ingredients (APIs) and combination products. Respitab can provide a cost-effective approach for new chemical entity (NCE) and generic pMDI products, simplifying manufacturing processes for low GWP propellants. Respitab can generate highly efficient aerosol properties and dose uniformity characteristics, reduce waste/API losses and facilitate scalability. i2c Pharma Services UK: +44 2920 757865 info@i2cpharm.co.uk www.i2cPharm.co.uk Inhaled drug and device development Phillips Medisize is a global pharmaceutical CDMO with design and development locations across three continents. e 2025 Vectura acquisition expanded our capabilities. Today, we specialize in innovative inhaled drug development, leveraging more than 25 years of experience to help bring your medicines to market. For inhalation and nasal routes of admin- istration, we offer formulation, device design and combination product development, as well as man- ufacturing services to support the growing global need for inhalation and nasal therapies. Our expertise includes small molecules, biologics, complex combi- nations and generic products for pMDI, DPI, nasal inhaler and nebulization devices. Phillips Medisize US: +1 715 245-4500 PMCBrandSupport@molex.com www.phillipsmedisize.com